AMDL Inc. Executive Chairman & CEO Douglas MacLellan offers expert insight during exclusive interview with The Wall Street Transcript
TUSTIN, Calif., April 29 /PRNewswire-FirstCall/ -- AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today its Executive Chairman and CEO Mr. Douglas MacLellan has been interviewed and featured in The Wall Street Transcript - a New York weekly investment news publication focused on bringing market news and analysis through exclusive interviews with Wall Street professionals, industry experts and corporate executives.
In an exclusive interview, Mr. MacLellan discusses AMDL's continued focus on becoming a premier pharmaceutical company in the growing $100B China market; the Company's regional expansion and distribution strategy in China; current financing efforts and financial targets for fiscal year 2009; and AMDL's worldwide commercialization strategy for its DR-70 (FDP) cancer test and Human Placenta Extract (HPE) skin care line.
Mr. MacLellan also provided opinion on China pharmaceutical industry saying, "Since the beginning of 2009 the stock market in China has gone up 30%, while the US, European, and other Asian markets have fallen. The Chinese market is going to be the force behind AMDL's sales and marketing for the next few years ... this is good because this market continues to grow and is expected to continue growing between 5-7% from a GDP perspective in 2009."
For the past four consecutive years AMDL has achieved over 100% year-over-year gross revenue growth. Mr. MacLellan provided further insight on AMDL's tremendous growth trajectory saying the Company's FY2009 growth prospects remain strong and executive management is confident AMDL will achieve its FY09 financial guidance of US $62-74 million - which represents another year of 100% growth.
AMDL is featured as the "#1 Small-Cap Stock Pick for 2009" by Flaherty Financial News (www.flahertyfinancialnews.com ), a New York-based investment newsletter, and named one of the Top 5 fastest growing publicly-traded companies in Orange County by international consulting group Deloitte.
The Wall Street Transcript executive interview of Mr. MacLellan has been published and is available on the WST website located at www.twst.com . For additional information on AMDL, its portfolio of international health and beauty products, and 2009 business strategy, visit the Company's website at www.amdl.com or contact AMDL Investor Relations at email@example.com .
Headquartered in Tustin, CA with operations in China, AMDL Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 500 people in the US and China.
Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
AMDL Contact: Kristine Szarkowitz Director-Investor Relations firstname.lastname@example.org (Tel:) 206.310.5323
|SOURCE AMDL Inc.|
Copyright©2009 PR Newswire.
All rights reserved